Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
GILD News
Gilead Sciences (NASDAQ:GILD) announced on Tuesday that the European Commission granted marketing authorization for its antiviral therapy lenacapavir as a twice...
Gilead (GILD) announced that the European Commission has granted marketing authorization for Yeytuo-the company’s twice-yearly injectable HIV-1 capsid inhibitor...
Gilead Sciences ((GILD)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off!...
Analyst ratings
71%
of 28 ratingsMore GILD News
Gilead Sciences ((GILD)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off!...
Gilead Sciences ((GILD)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off!...
Gilead Sciences ((GILD)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off!...
If you are staring at Gilead Sciences and wondering whether it is time to buy, hold, or sell, you are not alone. The stock has delivered a solid ride lately, wi...
After Reuters reported that CVS Health (CVS) will not cover Gilead’s (GILD) Yeztugo for HIV PrEP therapy in their commercial and ACA plans, Leerink is positive...
Shares in biopharmaceutical group Gilead Sciences (GILD) dropped 1% today after pharmacy firm CVS Health (CVS) gave the thumbs down to its new HIV medication....
As biotechnology companies increasingly seek innovative approaches to enhance cancer treatment, strategic acquisitions are becoming a key pathway for expanding...
